3 results
The objective of this study is to assess the safety and efficacy of the Veniti Vici* Venous Stent System in achieving patency of the target venous lesion through 36 months in patients who present with clinically significant chronic non-malignant…
Primary objective: Estimate the MTD and/or RDE of LDK378 as a single agent when administered orally to pediatric patients with ALK-activated tumors in the fasted and in fed stateSecondary objectives: Objective 1: Characterize the safety and…
The anti-TIM-3 monoclonal antibody MBG453 is a novel immunotherapeutic agent with promising activity seen in AML and MDS. The purpose of the current study is to assess clinical effects of MBG453 in combination with azacitidine in adult subjects with…